Coherus bails on TIGIT programme with Junshi
Phase 2Acquisition
There may be renewed hope around TIGIT inhibition, despite an overall disappointing track record for the target, but Coherus BioSciences has bounced it from its portfolio objectives. On Wednesday, Coherus disclosed in a US securities filing that it terminated the anti-TIGIT CHS-006 (JS006) programme it had partnered on with Shanghai Junshi Biosciences.
The move follows a portfolio review undertaken by Coherus following its $65-million stock deal to acquire Surface Oncology last September where it snagged an IL-27-targeted antibody in Phase II for lung and liver cancer, as well as another directed against CCR8 in early development for advanced solid tumours. At the time, the company said it would be looking to concentrate its efforts on the "most promising and/or competitively positioned" candidates in its pipeline.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.